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Themetabolic state of a bacterial cell influences its susceptibility to antibiotics. In this issue, Peng et al. (2015)
show that resistant bacteria can be sensitized to antibiotic treatment through the addition of exogenous me-
tabolites that stimulate central metabolic pathways and increase drug uptake.The role of metabolism in the bacterial
response to antibiotics has recently
garnered interest because of a rapid rise
in antibiotic resistance, a clear link
between metabolic function and cell
viability, and the lack of novel targets for
hard-to-treat infections. A large body of
evidence suggests that bacterial meta-
bolism is closely tied to antibiotic suscep-
tibility. Bacteria with reduced metabolism
are resistant or tolerant tomany classes of
antibiotics, while increased drug sensi-
tivity is linked to enhanced metabolism
(Allison et al., 2011; Bryan and VanDen El-
zen, 1977; Kohanski et al., 2007; Martı´nez
and Rojo, 2011). Little is known, however,
about the metabolic profiles of genetically
resistant bacterial populations. Peng et al.
address this topic in this issue of Cell
Metabolism.
To investigate the metabolic state of
resistant bacteria, Peng et al. (2015)
evolved Edwardsiella tarda (E. tarda), an
opportunistic pathogen in humans and
fish, against the aminoglycoside antibi-
otic, kanamycin. Resistant E. tarda strains
had altered metabolic profiles, with
defects observed in central metabolic
pathways (Figure 1A). Resistant strains
exhibited the greatest deficiencies in
glucose and alanine abundances. These
findings are consistent with previous
work in resistant strains of Stenotropho-
monasmaltophilia andPseudomonas aer-
uginosa (Alonso et al., 2004; Stickland
et al., 2010), which were found to exhibit
defects in central metabolism, specifically
glucose and amino acid metabolism.
It is generally accepted that the acquisi-
tion of genetic resistance determinants
results in a metabolic cost for bacteria,
such that susceptible bacteria will effi-154 Cell Metabolism 21, February 3, 2015 ª2ciently outcompete resistant bacteria in
the absence of selection pressures
(La´za´r et al., 2014). This notion is rooted
in the fact that constantly replicating large
plasmids containing resistance genes,
or producing enzymes that inactivate anti-
biotics, would lead to a large metabolic
burden. Several mechanisms of known
resistance have been documented,
ranging from drug-degrading enzymes to
efflux pumps. These mechanisms afford
different levels of protection for a popula-
tion of bacteria, and the metabolic impact
of each of these resistance mechanisms
varies depending on their fitness cost
(Martı´nez and Rojo, 2011). The bacterial
strains studiedbyPeng et al.were evolved
in vitro under the selection pressure of
kanamycin. However, the authors did not
sequence the strains to identify the muta-
tions and underlying resistance mecha-
nisms that arose. Therefore, it remains
unclear if the metabolic deficiencies
observed were specific to the evolved
mechanism of resistance or whether
they can be generalized across resistant
strains that are mechanistically distinct.
Given the metabolic deficiencies
observed in resistant strains of E. tarda,
Peng and co-authors hypothesized that
addition of the deficient metabolites could
increase the susceptibility of the resistant
bacteria to antibiotic treatment. Chal-
lenging kanamycin-resistant E. tarda
with alanine and/or glucose plus kana-
mycin indeed sensitized the bacteria to
the antibiotic. Additionally, cells treated
with alanine and glucose had higher
intracellular levels of kanamycin. This
enhancement in drug uptake was shown
to be a result of increased proton motive
force, due to greater flux through the015 Elsevier Inc.tricarboxylic acid (TCA) cycle (Figure 1B).
This work indicates that metabolite-
enabled increases in central metabolic
flux can enhance drug uptake and bacte-
rial killing in resistant bacteria.
Alanine and glucose supplementation
was also able to increase aminoglyco-
side-induced killing in lab-evolved beta-
lactam-resistant, quinolone-resistant, and
tetracycline-resistant strains of E. tarda.
The lethal effects of aminoglycoside treat-
ment were also enhanced with the addi-
tion of these metabolites in several other
human pathogens, including Klebsiella
pneumoniae, methicillin-resistant Staphy-
lococcus aureus, and Pseudomonas
aeruginosa. Biofilms and persisters of
clinical pathogenic isolates of E. tarda
were also successfully targeted with the
same approach. This is consistent with
previous work by Allison et al., which
showed that addition of exogenous me-
tabolites (e.g., glucose, mannitol, fruc-
tose) could stimulate central metabolic
pathways and enable aminoglycosides
to eradicate Escherichia coli and Staphy-
lococcus aureus persisters and biofilms
(Allison et al., 2011). Together, these
works show that metabolic stimuli can
boost the bactericidal effects of amino-
glycosides across many species in
different physiological states.
The addition of exogenous metabolites
to restore metabolic deficiencies offers an
attractive approach to treat drug-resistant
pathogens in combination with antibiotics
that would otherwise be ineffective (Mur-
ima et al., 2014). It is important to note,
however, that the metabolic burden on a
resistant pathogen is highly dependent
on the bacterial microenvironment and
the metabolic adaptations required for
AB
Figure 1. Exogenous Addition of Metabolites Enhances Antibiotic Uptake, Leading to Cell
Death
(A) Antibiotic-resistant cells have lower metabolite abundances, leading to reduced PMF, inhibited drug
uptake, and survival.
(B) Exogenous addition of alanine and/or glucose can enhance drug uptake and restore cell sensitivity.
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Previewscolonizing such a habitat. The work by
Peng et al. raises many questions about
the role of environmental metabolic sig-
nals in the efficacy of antibiotics. Bacteria
generate a large number of metabolites,
many of which have unknown or incom-
pletely understood biological functions,
and metabolites produced by one class
of bacteria can influence the antibiotic
susceptibility of neighboring bacteria
within a niche (Vega et al., 2013). Further
studies are needed to understand more
completely the role of metabolites in
in vivo infection microenvironments.
Along these lines, little is known about
the role of host metabolites in the regula-
tion of antibiotic efficacy. Interestingly,severe and recurrent infections tend to
manifest more frequently within hosts
that are immunocompromised, suggest-
ing that the host environment, including
the metabolome, could significantly influ-
ence the rate of infection, the efficacy of
antibiotics, and the generation of resis-
tance. Expanding on these studies will
provide insights into how bacterial and
host metabolism can influence antibiotic
efficacy, potentially leading to personal-
ized infection control strategies based
on a patient’s metabolic state.
Investigating the relationships between
bacterial metabolism and antibiotic sensi-
tivity can help to uncover novel strategies
for treating infections. The report by PengCell Metabolism 21et al. highlights the significance of the
metabolic environment in antibiotic resis-
tance and treatment strategies (Peng
et al., 2015). It will be important to build
upon this work and examine how the
metabolic state varies with different resis-
tance mechanisms and across different
environmental conditions. Further studies
may allow us to develop generalized
metabolic therapeutics as co-treatments
for already-prescribed antibiotics, there-
by expanding a rapidly shrinking arsenal
of effective therapies against resistant
and persistent infections.ACKNOWLEDGMENTS
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